115 results
DEFA14A
IMNM
Immunome Inc
26 Apr 24
Additional proxy soliciting materials
4:08pm
(as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material under § 240.14a-12
Immunome, Inc.
(Name … boxes that apply):
No fee required
Fee paid previously with preliminary materials
Fee computed on table in exhibit required by Item 25(b) per
8-K
EX-10.1
qlffz9tn3nk
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-1.1
u0m69
14 Feb 24
Other Events
4:11pm
424B5
peysqqo f0uc8vqy
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
9l2xh41hik sovu
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
EX-99.1
ewtoysy3dgf9cyy2hq
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.2
poo7fet2bf6zjvzgyt
13 Feb 24
Results of Operations and Financial Condition
4:10pm